Roche: FDA grants accelerated approval for liver cancer drug

(CercleFinance.com) - Swiss drugmaker Roche said on Wednesday the U.
S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Tecentriq in combination with Avastin for the treatment of people with advanced or metastatic hepatocellular carcinoma, an aggressive form of liver cancer with limited treatment options.

Preliminary data from the combination of Tecentriq and Avastin in this disease proved to be promising, Roche said.

Breakthrough therapy designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases.

Copyright (c) 2018 CercleFinance.com. All rights reserved.